Vaccine effectiveness of a single dose of quadrivalent human papillomavirus vaccine in Fijian women approximately 17 years following vaccination
- Project status: Active
Research areas: Infection, Immunity and Global Health > Asia Pacific Health
Assessing the long-term protection against 4-valent Human Papilloma Virus (HPV)
The challenges
The three-dose schedule of the licensed Human Papilloma Virus (HPV) vaccines have demonstrated excellent immunogenicity, safety and high efficacy against vaccine type HPV related disease.
However, the implementation of a three-dose school or community-based immunisation program for schoolgirls in resource-constrained countries like Fiji has been challenging due to the high cost of vaccine and the limited resources to vaccinate with multiple doses.
To address these challenges, many studies have explored alternative HPV dosage schedules.
Study purpose
This study aims to assess the long-term effectiveness of a single dose of the quadrivalent HPV (4vHPV) vaccine against HPV in Fijian women approximately 17 years following the HPV vaccination campaign conducted in 2008/2009.
Additionally, the study will assess immune responses in a subset of women who were unvaccinated, as well as those who received one, two, or three doses of the 4vHPV vaccine. These evaluations will take place approximately 17 years after their last dose.
The findings may help determine whether a single-dose schedule is a viable strategy for overcoming barriers to global HPV vaccine rollout globally.
Funders & collaborators
- Department of Foreign Affairs and Trade – Regional Health Partnerships
- Ministry of Health and Medical Services, Fiji
- Fiji National University
More information
Contact us
Asia-Pacific Heath
Murdoch Children's Research Institute
The Royal Children's Hospital
50 Flemington Road
Parkville VIC 3052
Australia
Email: show email address
Share //
